Arcutis Announces Publication Of Positive Safety And Efficacy Data Of ZORYVE Treatment For Pediatric Mild-to-Moderate Atopic Dermatitis

Arcutis Biotherapeutics +1.41% Pre

Arcutis Biotherapeutics

ARQT

24.53

24.53

+1.41%

0.00% Pre
Arcutis Announces Publication Of Positive Safety And Efficacy Data Of ZORYVE Treatment For Pediatric Mild-to-Moderate Atopic Dermatitis